Ana-Maria Vlădăreanu *, Delia Popescu **, Mirela Lăcătuș ***
* Dr. Ana-Maria Vlădăreanu, medic primar hematologie clinică și hemobiologie, șef de lucrări UMF “Carol Davila”, Clinica de Hematologie Colțea, București
** Prof. Dr. Delia Popescu, medic primar hematologie clinică și hemobiologie, Profesor UMF “Carol Davila”, Clinica de Hematologie Colțea, București
*** Mirela Lăcătuș, medic rezident
Abstract
Bendamustin was discovered in the sixties by Ozeposki and his research team from Jena Microbiological and Experimental Therapy Institute – Germany. The aim of its synthesis was to obtain a bifunctional alkilating agent. Water solubility was the major advantage of the new compound (comparatively to Chlorambucil for example). Anger et al. (18) have published the initial results of Bendamustin’s successfully clinical use in patients with plasmacytoma. Ribosepharm launched Bendamustin on the market in 1993, on the trade name of Ribomustin. It has begun to be widely used in the treatment of non-Hodgkin’s lymphomas.